oxytetracycline--anhydrous and Acne-Vulgaris

Oxytetracycline is a bacteriostatic antibiotic. Newly discovered, additional mechanisms of action include antioxidant, antiinflammatory and immynosupresive activity of oxytetracycline and other tetracyclines. These activities were the basis for developing therapy regimens with oxytetracycline in subantimicrobial doses. Due to its significant efficacy, limited adverse effects and low therapy costs, oxytetracycline at the dose of 500 mg per day is presently considered as therapy of choice in papulopustulous acne. Rosacea and perioral dermatitis are other indications. Topical oxytetracycline shows significant efficacy in primary and secondary skin infections with inflammatory reaction.

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Oxytetracycline; Rosacea

Topics: Acne Vulgaris; Administration, Topical; Benzoyl Peroxide; Clindamycin; Dicarboxylic Acids; Erythromycin; Humans; Miconazole; Oxytetracycline; Salicylates; Salicylic Acid; Tretinoin

Topics: Absorption; Acne Vulgaris; Bacteria; Bacteriuria; Bronchial Diseases; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; Chlortetracycline; Demeclocycline; Drug Eruptions; Humans; Infections; Kidney Diseases; Methacycline; Oxytetracycline; Protein Binding; Tetracycline; Tooth Discoloration

To determine the relative efficacy and cost-effectiveness of five of the most commonly used antimicrobial preparations for treating mild to moderate facial acne in the community; the propensity of each regimen to give rise to local and systemic adverse events; whether pre-existing bacterial resistance to the prescribed antibiotic resulted in reduced efficacy; and whether some antimicrobial regimens were less likely to give rise to resistant propionibacterial strains.. This was a parallel group randomised assessor-blind controlled clinical trial. It was a pragmatic design with intention-to-treat analysis. All treatments were given for 18 weeks, after a 4-week treatment free period. Outcomes were measured at 0, 6, 12 and 18 weeks.. Primary care practices and colleges in and around Nottingham and Leeds, and one practice in Stockton-on-Tees, England.. Participants were 649 people aged 12--39 years, all with mild to moderate inflammatory acne of the face.. Study participants were randomised into one of five groups: 500 mg oral oxytetracycline (non-proprietary) twice daily (b.d.) + topical vehicle control b.d.; 100 mg oral Minocin MR (minocycline) once daily (o.d.) + topical vehicle control b.d.; topical Benzamycin (3% erythromycin + 5% benzoyl peroxide) b.d. + oral placebo o.d.; topical Stiemycin (2% erythromycin) o.d. + topical Panoxyl Aquagel (5% benzoyl peroxide) o.d. + oral placebo o.d., and topical Panoxyl Aquagel (5% benzoyl peroxide) b.d. + oral placebo o.d. (the active comparator group).. The two primary outcome measures were: (1) the proportion of patients with at least moderate self-assessed improvement as recorded on a six-point Likert scale, and (2) change in inflamed lesion count (red spots).. The best response rates were seen with two of the topical regimens (erythromycin plus benzoyl peroxide administered separately o.d. or in a combined proprietary formulation b.d.), compared with benzoyl peroxide alone, oxytetracycline (500 mg b.d.) and minocycline (100 mg o.d.), although differences were small. The percentage of participants with at least moderate improvement was 53.8% for minocycline (the least effective) and 66.1% for the combined erythromycin/benzoyl peroxide formulation (the most effective); the adjusted odds ratio for these two treatments was 1.74 [95% confidence interval (CI) 1.04 to 2.90]. Similar efficacy rankings were obtained using lesion counts, acne severity scores and global rating by assessor. Benzoyl peroxide was the most cost-effective and minocycline the least cost-effective regimen (ratio of means 12.3; difference in means -0.051 units/GBP, 95% CI -0.063 to -0.039). The efficacy of oxytetracycline was similar to that of minocycline, but at approximately one-seventh of the cost. For all regimens, the largest reductions in acne severity were recorded in the first 6 weeks. Reductions in disability scores using the Dermatology Quality of Life Scales were largest for both topical erythromycin-containing regimens and minocycline. The two topical erythromycin-containing regimens produced the largest reductions in the prevalence and population density of cutaneous propionibacteria, including antibiotic-resistant variants, and these were equally effective in participants with and without erythromycin-resistant propionibacteria. The clinical efficacy of both tetracyclines was compromised in participants colonised by tetracycline-resistant propionibacteria. None of the regimens promoted an overall increase in the prevalence of antibiotic-resistant strains. Systemic adverse events were more common with the two oral antibiotics. Local irritation was more common with the topical treatments, particularly benzoyl peroxide. Residual acne was present in most participants (95%) at the end of the study.. The response of mild to moderate inflammatory acne to antimicrobial treatment in the community is not optimal. Only around half to two-thirds of trial participants reported at least a moderate improvement over an 18-week study period; extending treatment beyond 12 weeks increased overall benefit slightly. Around one-quarter dropped out when using such treatments, and 55% sought further treatment after 18 weeks. Topical antimicrobial therapies performed at least as well as oral antibiotics in terms of clinical efficacy. Benzoyl peroxide was the most cost-effective and minocycline the least cost-effective therapy for facial acne. The efficacy of all three topical regimens was not compromised by pre-existing propionibacterial resistance. Benzoyl peroxide was associated with a greater frequency and severity of local irritant reactions. It is suggested that the use of a combination of topical benzoyl peroxide and erythromycin gives less irritation and better quality of life. There was little difference between erythromycin plus benzoyl peroxide administered separately and the combined proprietary formulation in terms of efficacy or local irritation, except that the former was nearly three times more cost-effective. The data on cost-effectiveness, and outcomes in patients with resistant propionibacterial floras, did not support the first line use of minocycline for mild to moderate inflammatory acne of the face. Three priority areas for clinical research in acne are: defining end-points in acne trials (i.e. what is a satisfactory outcome?); developing and validating better patient-based measures for assessing treatment effects on facial and truncal acne; and exploring patient characteristics that may modify treatment effects (efficacy and tolerability).

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Benzoyl Peroxide; Child; Cost-Benefit Analysis; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Erythromycin; Humans; Minocycline; Oxytetracycline; Propionibacterium; Quality of Life; Treatment Outcome

One hundred and six patients with acne vulgaris of the face were treated for 10 weeks with either topical meclocycline sulfosalicylate, topical benzoyl peroxide or both preparations. A randomized, double-blind parallel group study was used. Benzoyl peroxide proved more effective than meclocycline in reducing acne lesion counts, while local side effects were more common in the benzoyl peroxide-treated patients. The combined treatment was of intermediate efficacy with fewer local side effects.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Infective Agents, Local; Benzoyl Peroxide; Child; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Oxytetracycline

A proprietary topical tetracycline preparation (Topicycline) was compared with an alcohol-based 5% benzoyl-peroxide gel and with oral oxytetracycline (250 mg twice daily) using a randomized group-comparative double-blind study in 69 patients with mild to moderate acne. Facial acne grades improved significantly in all three treatment groups over the 12-week study period but chest acne grades did not change significantly and only oxytetracycline produced a significant improvement in back grade. All three treatment groups produced a significant reduction in facial inflamed and non-inflamed lesions apart from oxytetracycline which failed to produce a significant reduction in inflamed lesions. However, there were no overall significant differences between the three treatment groups either in improvement of acne grade or in reduction of inflamed and non-inflamed lesions. We conclude that topical tetracycline is as effective as either 5% benzoyl-peroxide gel or 250 mg oxytetracycline twice daily in the treatment of mild to moderate acne.

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Benzoyl Peroxide; Child; Drug Administration Schedule; Female; Humans; Male; Oxytetracycline; Tetracycline

Two percent metronidazole and 5% benzoyl peroxide cream was evaluated in four clinical trials. It could be shown that this test cream was significantly better than 5% benzoyl peroxide jelly alone, and significantly better than a placebo cream. It was also shown that 2% metronidazole and 5% benzoyl peroxide cream was equal to systemic oxytetracycline therapy. The advisability of the combination of metronidazole and benzoyl peroxide was simultaneously discussed.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Benzoyl Peroxide; Drug Therapy, Combination; Female; Gels; Humans; Male; Metronidazole; Military Personnel; Oxytetracycline; Tablets; Treatment Outcome

In a multicentre general practice open study, 338 acne sufferers were treated with Minocin 50 mg b.d. (254 for 12 weeks). A highly significant improvement trend (p less than 0.0001) was found following analysis of visual analogue scales measuring (i) severity of acne, (ii) area covered by acne, (iii) number of inflamed lesions, (iv) density of acne lesions. Over all, 79% of patients thought the therapy to be effective or very effective; 70% of patients continued on the same therapy after the study period. Mean first improvement was noted by the patients after 4 1/2 weeks of treatment. One hundred and twenty-two patients had taken prior oxytetracycline therapy, of these, ninety-four (77%) stopped oxytetracycline therapy because of lack of efficacy. After treatment of these oxytetracycline failures with Minocin, a highly significant improvement trend (p less than 0.0001) of acne was again seen. In this group, 75% of patients thought the Minocin therapy to be effective or very effective; 69% continued Minocin therapy after the study period. In all, 74% of patients having received prior oxytetracycline thought that Minocin therapy was better than their previous therapy. Ninety-three patients had received either no previous therapy or topical therapy alone. Once again Minocin treatment resulted in a highly significant improvement trend (p less than 0.0001) in the severity of acne. Seventy six (82%) of these patients thought that Minocin therapy was effective or very effective. A total of 73% of patients continued with Minocin therapy following the study period. Adverse events were noted in 6% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Acne Vulgaris; Adolescent; Adult; Clinical Trials as Topic; Family Practice; Female; Humans; Male; Minocycline; Oxytetracycline; Tetracyclines; Time Factors

The clinical effect on acne vulgaris of topical treatment with meclocycline sulfosalicylate and systemic treatment with peroral tetracycline (500 mg daily) was compared in a double-blind study of 60 patients treated for 8 weeks. The reducing effect of Meclosorb cream and tetracycline tablets on the number of closed comedones, pustules, papules and cysts was marked and not significantly different. The effect of Meclosorb on open comedones was weak and of slow onset. No side effects were registered. Topical treatment with Meclosorb is an effective and safe alternative to systemic tetracycline treatment of acne vulgaris.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxytetracycline; Random Allocation; Tetracycline

Ten institutions participated in a controlled clinical trial in order to evaluate the efficacy of topical meclocycline and erythromycin in comparison to placebo with regard to papulopustular acne. Both drugs had been incorporated in the same galenic formulation that served as placebo. The vehicle employed in this study guaranteed equally favorable drug relies for both preparations. At the end of the trial, 419 patients could be evaluated for efficacy. As impartial criterion for evaluation, the number of inflammatory lesions on the right side of the face was counted before and after three months of treatment. In addition, we recorded the patients' and physicians' overall judgment at the end of the study. As compared with placebo, meclocycline as well as erythromycin brought about statistically significant improvement already after two months of treatment. After three months, the results were statistically very highly significant (p less than 0.001). At any time of the study, there could not be demonstrated any difference between the two groups treated with meclocycline and erythromycin.

Topics: Acne Vulgaris; Administration, Topical; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Double-Blind Method; Erythromycin; Humans; Oxytetracycline; Suppuration

Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Inflammation; Male; Oxytetracycline; Random Allocation; Trimethoprim

Meclocycline sulfosalicylate is a broad spectrum antimicrobial agent that was synthesized in 1960 and has been marketed abroad for several years. Clinical studies in the United States to date involve 351 patients. The results of a regimen using topically applied meclocycline sulfosalicylate, 1 percent, as the sole treatment are examined. Overall 82 percent of the patients treated with the active preparation experienced clinical improvement in a twice daily application regimen. Excellent of good results were obtained in 62.3 percent of patients treated with meclocycline sulfosalicylate cream as compared with 27.5 percent of those treated with the cream vehicle alone. The median percent reduction in the number of inflammatory lesions of acne among patients treated for 11 weeks was 57.1 percent. Rapid response was noted at week 5, with nearly a 50 percent median reduction in papules and pustules. The low incidence of local adverse effects was noteworthy. Only one case of contact dermatitis possibly related to treatment was reported among the patients studied.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Oxytetracycline

It has been well documented that acne vulgaris usually responds well to long-term systemic tetracycline therapy. However, not all patients respond satisfactorily due to drug intolerance, adverse side effects such as fixed drug eruptions, moniliasis, photosensitivity, and gastric irritation. A double-blind study comparing trimethoprim/sulfamethoxazole with oxytetracycline in the management of acne vulgaris has demonstrated that trimethoprim/sulfamethoxazole is an equally effective and as safe therapeutic agent as oxytetracycline. The results of this study are shown to confirm the works of other authors.

Topics: Acne Vulgaris; Double-Blind Method; Drug Combinations; Female; Humans; Male; Oxytetracycline; Sulfamethoxazole; Trimethoprim

Topics: Acne Vulgaris; Adolescent; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Male; Oxytetracycline; Sulfamethoxazole; Trimethoprim

With a double-blind technique, the effects of oral zinc and tetracyclines were compared in 37 patients with moderate and severe acne. No difference in effect between the treatments was seen and no side-effects were noted in any group. After 12 weeks of treatment, the average decrease in the acne score was about 70% in both groups.

Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Oxytetracycline; Zinc

Two groups of 27 and 23 patients with acne vulgaris were first treated for a period of one week with 1 g oxytetracycline a day p.o. In a second treatment period of 6 weeks the first group received 100 mg oxytetracycline a day p.o. and the second group a combination of 100 mg oxytetracycline and 1.2 g sodiumbituminosulfonates a day p.o. In the third treatment period, similarly continued for 6 weeks, the method was reversed. Gastric juice-insoluble preparations were used for the investigation. All criteria for a double-blind study were considered. Amount and composition of the skin surface lipids were analysed before beginning the treatment, at the end of the 2nd and at the end of the 3rd treatment period. The combination of both agents in gastric juice-insoluble preparations suppresses to a great extent the known effects brought about by the substances separately, namely the reduction in free fatty acids and the decrease in the skin surface lipids. The findings also show that the reduction of the free fatty acids was in a limited time observed only in patients treated with 100 mg oxytetracycline a day p.o. if they had been treated in the beginning of this therapy with a higher dosage of tetracycline.

Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Drug Interactions; Fatty Acids, Nonesterified; Female; Humans; Intestinal Absorption; Lipid Metabolism; Male; Oxytetracycline; Skin; Tablets, Enteric-Coated

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Child; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Ointments; Oxytetracycline; Placebos; Tretinoin; Vitamin A

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Child; Clinical Trials as Topic; Drug Therapy, Combination; Erythema; Evaluation Studies as Topic; Female; Humans; Male; Ointments; Oxytetracycline; Placebos; Vitamin A

Topics: Acne Vulgaris; Adolescent; Adult; Child; Female; Folic Acid Antagonists; Humans; Male; Oxytetracycline; Photography; Pyrimidines; Sulfamethoxazole

Topics: Acne Vulgaris; Clinical Trials as Topic; Humans; Oxytetracycline; Placebos

Topics: Acne Vulgaris; Adolescent; Adult; Anti-Bacterial Agents; Clinical Trials as Topic; Erythema; Female; Humans; Male; Oxytetracycline

Topics: Acne Vulgaris; Chlortetracycline; Clinical Trials as Topic; Humans; Oxytetracycline

An analytical method for the simultaneous determination of 6 antibiotics (minocycline, oxytetracycline, tetracycline hydrochloride, chlorotetracycline hydrochloride, doxycycline hydrochloride and chloramphenicol) and metronidazole in acne removal products of cosmetic was established using high performance liquid chromatography (HPLC). The drugs in the sample were extracted with methanol. The separation was performed on an Agilent ZORBAX SB-C18 column (250 mm x 4.6 mm, 5 microm) at 20 degrees C with methanol, acetonitrile and 0.002 mol/L oxalic acid solution as mobile phases with gradient elution at a flow rate of 0.8 mL/min. The detection was performed by a diode array detector (DAD) at 268 nm. The injection volume was 10 microL. The quantification was performed by external standard method. The calibration curves showed good linearity within the range of 1 - 30 mg/L with the correlation coefficients no less than 0.997 0. The detection limits were in the range of 1.1 - 1.2 microg/g. The recoveries were between 91.9% and 107.7% in three spiked levels of 5, 10 and 20 mg/L with the relative standard deviations (RSDs) of 0.13% - 1.74%. The method was used in the analysis of acne removal products, and metronidazole was found in 15% of the total test samples. The method is rapid, sensitive, accurate, effective in separation, and can be used in the determination of the six antibiotics and metronidazole in acne removal products.

Topics: Acne Vulgaris; Anti-Bacterial Agents; Anti-Infective Agents; Chromatography, High Pressure Liquid; Cosmetics; Humans; Metronidazole; Minocycline; Oxytetracycline; Tetracycline

Previous studies have shown an association between isotretinoin and inflammatory bowel disease (IBD). The majority of patients prescribed isotretinoin for their acne are previously on an extended course of antibiotics. Therefore, it is important to consider antibiotic use as a confounding variable for the development of IBD.. We performed a retrospective cohort study using The Health Improvement Network database of the United Kingdom. We identified 94,487 individuals with acne who were followed up by a general practitioner for 406,294 person-years.. >A prescription for minocycline was received by 24,085 individuals, for tetracycline/oxytetracycline by 38,603 individuals, and doxycycline by 15,032 individuals. IBD was noted in 41 individuals exposed to minocycline, 79 individuals exposed to tetracycline/oxytetracycline, 32 individuals exposed to doxycycline, and 55 (0.11%) individuals not exposed to any of these antibiotics. The hazard ratio (HR) for developing IBD for any exposure to a tetracycline antibiotic was 1.39 (1.02, 1.90). HRs for individual antibiotics were 1.19 (0.79, 1.79) for minocycline, 1.43 (1.02, 2.02) for tetracycline/oxytetracycline, and 1.63 (1.05, 2.52) for doxycycline. For ulcerative colitis, the associations (HR) were 1.10 (0.76, 1.82) for minocycline, 1.27 (0.78, 2.07) for tetracycline/oxytetracycline, and 1.06 (0.53, 2.13) for doxycycline. For Crohn's disease (CD), the associations (HR) were 1.28 (0.72, 2.30) for minocycline, 1.61 (0.995, 2.63) for tetracycline/oxytetracycline, and 2.25 (1.27 4.00) for doxycycline.. Tetracycline class antibiotics, and particularly doxycycline use may be associated with the development of IBD, particularly CD. Potential confounding by previous doxycycline exposure should be considered when assessing whether treatment with other acne medications increases the risk of IBD.

Topics: Acne Vulgaris; Chi-Square Distribution; Confounding Factors, Epidemiologic; Dermatologic Agents; Doxycycline; Drug Interactions; Female; Humans; Inflammatory Bowel Diseases; Isotretinoin; Male; Minocycline; Oxytetracycline; Proportional Hazards Models; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Tetracycline; United Kingdom; Young Adult

Topics: Acne Vulgaris; Anti-Bacterial Agents; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Drug Interactions; Ethinyl Estradiol; Female; Humans; Oxytetracycline

Topics: Acne Vulgaris; Anti-Bacterial Agents; Family Practice; Humans; Oxytetracycline; Patient Acceptance of Health Care; Pharmacies; Primary Health Care; United Kingdom

Apert's syndrome is a congenital disorder characterized by the premature fusion of the cranial sutures and early epiphyseal closure. Severe pustular acne is a common feature. We report a case that failed to respond to conventional antibiotic treatment but resolved following isotretinoin therapy. The patient's permanent tracheostomy proved a management challenge during isotretinoin treatment. The role of androgen-sensitivity is discussed in relation to the skin and bones.

Topics: Acne Vulgaris; Acrocephalosyndactylia; Anti-Bacterial Agents; Child; Humans; Isotretinoin; Male; Oxytetracycline; Treatment Failure

Topics: Acne Vulgaris; Anti-Bacterial Agents; Humans; Minocycline; Oxytetracycline; Tetracycline

Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Infant; Male; Oxytetracycline; Rosacea

The effects of systemically administered oxytetracycline and erythromycin in a guinea pig model of acne-type inflammation were assessed histologically and by tissue measurement techniques. It was found that oxytetracycline significantly reduced the volume and maximum area of inflammation compared with both control and erythromycin treated groups. Oxytetracycline also altered the morphology of the inflammatory infiltrate significantly reducing the proportion of polymorphonuclear leucocytes present. In this model, erythromycin did not alter the inflammatory response but did seem to reduce the amount of transepidermal elimination of inflammatory debris.

Topics: Acne Vulgaris; Animals; Disease Models, Animal; Erythromycin; Guinea Pigs; Inflammation; Oxytetracycline; Skin

Topics: Acne Vulgaris; Adult; Aged; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Middle Aged; Oxytetracycline; Patch Tests; Photosensitivity Disorders

Treatment of acne prior to referral was recorded retrospectively in 72 patients alleged to have responded inadequately; 60% had used benzoyl peroxide (BP) but most applied it to lesions only. Although 86% had used tetracycline, most did not take it correctly for maximum absorption and took less than 1 g/day. Most patients used both drugs for less than three months. Eight-two patients referred because of inadequate response were treated with: (I) 5% benzoyl peroxide (BP) (23 patients); (II) 5% BP and 0.5 g/day oxytetracycline (OTC) (24 patients); (III) 5% BP and 1 g/day OTC (18 patients); (IV) 5% BP and 1.5 g/day OTC (17 patients). BP was applied incrementally from 30 min up to 8-10 hours daily to the entire area affected and OTC taken as a single morning dose. Median grade of severity (0-10 analogue scale) fell by 2 in Groups I and II (P less than 0.05), by 2.5 in Group III (P less than 0.05) and by 3 in Group IV (P less than 0.05); number of lesions fell by 56% +/- 7% (s.e.), (P less than 0.001) 70% +/- less than 10% (P less than 0.001), 75% +/- 8% (P less than 0.001) and 78% +/- 10% (P less than 0.001) respectively and treatment was well tolerated. Thus, although effective drugs are frequently prescribed in acne, method of use, dose and duration are likely to determine response.

Topics: Acne Vulgaris; Adolescent; Adult; Benzoyl Peroxide; Drug Administration Schedule; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Oxytetracycline; Peroxides; Retrospective Studies

Topics: Acne Vulgaris; Adolescent; Drug Stability; Drug Storage; Fanconi Syndrome; Humans; Male; Oxytetracycline

Topics: Acne Vulgaris; Adolescent; Diagnosis, Differential; Drug Therapy, Combination; Humans; Male; Oxytetracycline; Prednisolone

Topics: Acne Vulgaris; Belize; Humans; Male; Oxytetracycline; Tropical Climate

The levels of Propionibacterium acnes (P. acnes) and members of the Micrococcaceae were enumerated in two separate studies. The first investigation on the foreheads of thirty-five mild and thirty-five moderate acne patients showed no significant difference in the bacterial populations of the two groups. The second investigation of twelve patients on 250 mg tetracycline twice daily for 3 months showed no significant difference compared to pre-treatment data in the bacterial population during the successful treatment period. The data indicate that greater numbers of bacteria are not associated with increasing severity of acne and that the effectivenss of oral tetracycline in treating the disease can not be explained by a reduction in the number of viable bacteria.

Topics: Acne Vulgaris; Adolescent; Adult; Humans; Micrococcaceae; Oxytetracycline; Propionibacterium acnes

Topics: Acne Vulgaris; Adult; Female; Humans; Oxytetracycline; Photosensitivity Disorders; Porphyrias

Topics: Acne Vulgaris; Adolescent; Adult; Clindamycin; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Oxytetracycline; Sulfamethoxazole; Trimethoprim

Topics: Acne Vulgaris; Administration, Topical; Chloramphenicol; Diagnosis, Differential; Humans; Oxytetracycline; Tetracyclines; Tretinoin

Topics: Acne Vulgaris; Humans; Ointments; Oxytetracycline; Resorcinols; Salicylates; Sulfur

Topics: Acne Vulgaris; Contraceptives, Oral; Diet Therapy; Minocycline; Oxytetracycline; Vitamin A

Topics: Acne Vulgaris; Ampicillin; Chloramphenicol; Erythromycin; Escherichia coli; Female; Humans; Male; Oxytetracycline; Penicillin Resistance; Rectum; Streptomycin; Sulfonamides; Time Factors

Topics: Acne Vulgaris; Anti-Bacterial Agents; Gonorrhea; Humans; Oxytetracycline; Penicillin Resistance; Penicillins; Sexually Transmitted Diseases; Syphilis

Topics: Accidents, Occupational; Acne Vulgaris; Anti-Infective Agents, Local; Biological Assay; Blood Proteins; Chromatography, Gas; Dermatitis, Occupational; Dioxins; Explosions; Glycosuria; Humans; Liver Function Tests; Male; Oxytetracycline; Quaternary Ammonium Compounds

Topics: Acne Vulgaris; Adolescent; Adult; Body Weight; Child; Female; Humans; Male; Middle Aged; Oxytetracycline; Recurrence; Rosacea; Time Factors

Topics: Acne Vulgaris; Cholesterol; Chromatography, Thin Layer; Fatty Acids, Nonesterified; Humans; Oxytetracycline; Skin; Waxes

Topics: Acne Vulgaris; Cholesterol; Chromatography, Gas; Fatty Acids; Humans; Lipids; Oxytetracycline; Skin

Topics: Acne Vulgaris; Adolescent; Adult; Humans; Male; Oxytetracycline

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Alopecia; Anti-Inflammatory Agents; Cheilitis; Child; Child, Preschool; Dermatitis; Dermatitis, Contact; Dermatitis, Exfoliative; Eczema; Eczema, Dyshidrotic; Female; Herpes Zoster; Humans; Hydrocortisone; Infant; Infant, Newborn; Male; Neurodermatitis; Ointments; Oxytetracycline; Pityriasis; Prednisolone; Pyoderma; Skin Diseases

Topics: Acne Vulgaris; Humans; Oxytetracycline

Topics: Acne Vulgaris; Humans; Oxytetracycline

Topics: Acne Vulgaris; Anti-Bacterial Agents; Enterobacteriaceae; Erythromycin; Humans; Intestines; Oxytetracycline; Penicillins

Topics: Acne Vulgaris; Humans; Oxytetracycline